BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//American Liver Foundation - ECPv6.13.2.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://liverfoundation.org
X-WR-CALDESC:Events for American Liver Foundation
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240301T000000
DTEND;TZID=America/New_York:20250329T235959
DTSTAMP:20260422T062510
CREATED:20240805T211801Z
LAST-MODIFIED:20250327T163642Z
UID:10001298-1709251200-1743292799@liverfoundation.org
SUMMARY:Evolution of HER2-Targeted Therapy in Gastroesophageal Adenocarcinoma (GEA)
DESCRIPTION:We've collaborated with Medscape Oncology Global and Hope for Stomach Cancer to present a CME opportunity for health care professionals seeking to better understand established and emerging data related to HER2-targeted therapies in GEA. This on-demand course is available for continuing education credit until 3/29/25. \nUpon completion of this activity\, participants will: \n\nHave increased knowledge regarding the\n\nBiological rationale for using bispecific antibodies to target HER2 in GEA\n\n\nHave greater competence related to\n\nSelecting the most appropriate anti-HER2 therapy for a patient with HER2-positive GEA\nManaging adverse events associated with anti-HER2 therapies for patients with HER2-positive GEA\n\n\nDemonstrate greater confidence in their ability to\n\nCollaborate with the patient when developing a treatment plan for their HER2-positive GEA\n\n\n\nLearn more and register for this course: https://liver.fyi/HER2GEA \n 
URL:https://liver.fyi/HER2GEA#new_tab
LOCATION:On-Demand
CATEGORIES:Programs
ATTACH;FMTTYPE=image/png:https://liverfoundation.org/wp-content/uploads/2024/08/Fact-Sheet-What-Does-Your-Liver-Do.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240610T000000
DTEND;TZID=America/New_York:20240930T235959
DTSTAMP:20260422T062510
CREATED:20240611T153023Z
LAST-MODIFIED:20240611T153023Z
UID:10001054-1717977600-1727740799@liverfoundation.org
SUMMARY:Updates on Hepatitis B and C for Patients
DESCRIPTION:
URL:https://liverfoundation.org/resource-center/videos/updates-on-hepatitis-b-and-c-for-patients/
LOCATION:On-Demand
CATEGORIES:Programs
ATTACH;FMTTYPE=image/png:https://liverfoundation.org/wp-content/uploads/2024/06/Updates-on-Hepatitis-B-and-C-for-patients.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240910T190000
DTEND;TZID=America/New_York:20240910T200000
DTSTAMP:20260422T062510
CREATED:20240730T144142Z
LAST-MODIFIED:20240730T144650Z
UID:10001151-1725994800-1725998400@liverfoundation.org
SUMMARY:PBC & PSC: Diagnosing\, Treating\, and Monitoring. An ALF and CLF Collaboration
DESCRIPTION:Being diagnosed with a genetic liver disease can be overwhelming\, and understanding your condition can be a challenge. This webinar offers some guidance and education on the causes\, symptoms and diagnoses of primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) along with updates on the latest research and treatment options. As with most liver diseases\, PBC and PSC may come with daily challenges\, dietary changes\, and side effects from medications used to treat the conditions. Please join us on September 10\, at 7pm ET to discuss these issues and more with patients and medical experts from Canada and the US. To register\, please RSVP below.
URL:https://secure.liver.ca/site/SPageServer/?NONCE_TOKEN=F2CC87FD28458904ECAA5E5AAE0FC3EB&pagename=events_session_lrweb24#new_tab
LOCATION:Virtual
CATEGORIES:Programs
ATTACH;FMTTYPE=image/jpeg:https://liverfoundation.org/wp-content/uploads/2022/08/ALF-Brand-Refresh-1280x720-1.jpg
END:VEVENT
END:VCALENDAR